Atossa Genetics Stock to Reverse Split on Monday, February 2nd (NASDAQ:ATOS)

Shares of Atossa Genetics Inc. (NASDAQ:ATOS) are scheduled to reverse split before the market opens on Monday, February 2nd. The 1-15 reverse split was announced on Monday, January 26th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 30th.

Atossa Genetics Stock Performance

ATOS stock opened at $0.62 on Thursday. The company has a 50 day moving average price of $0.70 and a two-hundred day moving average price of $0.80. The stock has a market capitalization of $79.62 million, a P/E ratio of -2.57 and a beta of 1.09. Atossa Genetics has a one year low of $0.55 and a one year high of $1.29.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). Research analysts forecast that Atossa Genetics will post -0.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on ATOS. Zacks Research cut Atossa Genetics from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. Finally, Ascendiant Capital Markets increased their price target on shares of Atossa Genetics from $7.75 to $8.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hudson Bay Capital Management LP acquired a new stake in shares of Atossa Genetics in the second quarter worth $26,000. Gallagher Capital Advisors LLC purchased a new stake in Atossa Genetics during the 3rd quarter worth $27,000. JPMorgan Chase & Co. increased its holdings in Atossa Genetics by 1,294.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock valued at $33,000 after purchasing an additional 35,474 shares in the last quarter. Bank of America Corp DE raised its position in Atossa Genetics by 55.7% in the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after purchasing an additional 35,629 shares during the period. Finally, Catalyst Funds Management Pty Ltd acquired a new position in shares of Atossa Genetics during the second quarter worth about $49,000. 12.74% of the stock is owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.